NCT04839146View on ClinicalTrials.gov

Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

December 30, 2021

Study Completion Date

February 25, 2022

Conditions
Covid19Severe Acute Respiratory SyndromeSARS-CoV-2 Infection
Interventions
BIOLOGICAL

ABNCoV2 Vaccine

SARS-CoV-2 vaccine

Trial Locations (1)

6525GA

Radboud univserity medical center, Nijmegen

All Listed Sponsors
collaborator

European Union

OTHER

lead

Radboud University Medical Center

OTHER

NCT04839146 - Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) | Biotech Hunter | Biotech Hunter